Local Radiotherapy Affects Drug Pharmacokinetics—Exploration of a Neglected but Significant Uncertainty of Cancer Therapy

Yu-Jen Chen, MD, PhD*,1,2,3, Tung-Hu Tsai, PhD*,1,4, Li-Ying Wang, PhD5,6, and Chen-Hsi Hsieh, MD, PhD1,7,8

Abstract

Purpose: Concurrent chemoradiation therapy is the mainstay of treatment for many types of malignancies. However, concurrent chemoradiation therapy is associated with a greater number of systemic adverse effects than radiotherapy or chemotherapy alone.

Summary: Pharmacokinetics is the study of a drug and/or its metabolite kinetics in the body, including absorption, distribution, metabolism, and elimination. The incidences of adverse effects are markedly higher in patients who receive concurrent chemoradiation therapy than in those who receive either radiotherapy or chemotherapy alone. This phenomenon implies that irradiation affects the pharmacokinetics of cytotoxic agents, namely the radiotherapy–pharmacokinetic phenomenon. Experimental animal studies have shown that local irradiation affects the systemic pharmacokinetics of 5-fluorouracil and cisplatin at both low dose (simulating generous dose distributed to normal tissues) and daily practice dose (mimicking therapeutic dose to target volumes). These effects are significant in the circulation of blood and lymphatic system as well as in the hepatobiliary excretion. Furthermore, recent studies have demonstrated that matrix metalloproteinase-8 plays an important role in the radiotherapy–pharmacokinetic phenomenon. Conclusion: In the present review, we provide a general overview of the radiotherapy–pharmacokinetic phenomenon and discuss the possible mechanisms governing the phenomenon.

Keywords

concurrent chemoradiation therapy, pharmacokinetics, RT-PK phenomenon, radiotherapy, uncertainty

Abbreviations

3DCRT, 3-dimensional conformal radiotherapy; 5-FU, 5-fluorouracil; 5-FDH2, 5-fluoro-5,6-dihydro-uracil; AUC, area under the curve; CCRT, concurrent chemoradiation therapy; CDDP, cisplatin; DPD, dihydropyrimidine dehydrogenase; ESTRO, European Society for Radiotherapy and Oncology; GI, gastrointestinal; IL-6, interleukin 6; IMRT, intensity-modulated radiotherapy; JNK, c-Jun NH2-terminal kinase; MAPK, mitogen-activated protein kinase; MMP-8, matrix metalloproteinase-8; PI3 K, phosphatidylinositol (PtdIns) 3-kinases; PMNs, polymorphonuclear neutrophils; PIP3, PtdIns(3,4,5)P3; PK, pharmacokinetics; PVI, protracted venous infusion; RT-PK, radiotherapy–pharmacokinetic; ROS, reactive oxygen species; TNF-α, tumor necrosis factor α.

Received: June 03, 2017; Revised: September 02, 2017; Accepted: September 20, 2017.

* Authors Yu-Jen Chen and Tung-Hu Tsai contributed equally to this article.

1 Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
2 Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan
3 Department of Medical Research, Mackay Memorial Hospital, Taipei, Taiwan
4 Department of Chemical Engineering, National United University, Miaoli, Taiwan
5 School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, Taiwan
6 Physical Therapy Center, National Taiwan University Hospital, Taipei, Taiwan
7 Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan
8 Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, Taipei, Taiwan

Corresponding Author:
Chen-Hsi Hsieh, MD, PhD, Department of Radiology, Division of Radiation Oncology, Far Eastern Memorial Hospital, No. 21, Sec. 2, Nanya S. Rd., Banciao Dist., New Taipei City 220, Taiwan.
Email: chenciab@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Background

Concurrent chemoradiation therapy (CCRT) comprises the administration of cytotoxic agents in conjunction with radiation therapy as treatment for advanced stage cancer. Cisplatin (CDDP) and 5-fluorouracil (5-FU) are the most commonly used cytotoxic agents in CCRT and are known to increase the relative radiosensitivity and radiosensitization of hypoxic cells,1,2 synchronize and redistribute tumor cells in cell cycle G2 and M phases,3,4 kill S phase cells,5 inhibit repair of DNA double-strand breaks,6 suppress tumor neovascularization,7 and strengthen the killing effect of radiation.8-10 Chemotherapeutic regimens that named as metronomic regimens are delivering the chemotherapeutic drugs with the low, less toxic doses, prolonged periods of time, and no extended drug-free breaks by close regular administration.11-13 The main targets of metronomic chemotherapy are the endothelial cells of the growing vasculature of a tumor.11,14 These characteristics of CDDP and 5-FU as radiosensitizers contribute to the improved locoregional control and survival rates in patients with locally advanced cancer.15-23

However, the incidence of adverse effects such as hematologic, gastrointestinal (GI), and severe acute toxicities is markedly higher in patients who receive CCRT with 5-FU- or CDDP-base regimen than in those who receive either radiotherapy or chemotherapy alone, no matter of neoadjuvant setting, definitive setting, or adjuvant setting.15,16,18,21-29 Pharmacokinetics (PK) is the study of kinetics of absorption, distribution, metabolism, and excretion of drugs and their corresponding pharmacologic, therapeutic, or toxic responses in man and animals.30 Absorption is defined as the process by which a drug proceeds from the site of administration to the site of measurement (usually blood, plasma, or serum). Distribution is the process of reversible transfer of drug to and from the site of measurement (usually blood or plasma). Metabolism is the process of a conversion of one chemical species to another chemical species. Excretion is defined as the irreversible loss of a drug in a chemically unchanged or unaltered form.30

The combinations of certain drugs can mimic, increase, or reduce the effects of one or all components, resulting in clinically important interactions that was proven by PK parameters.31-33 For example, St-John's-wort (Hypericum perforatum) reduces the plasma concentrations (and/or increases the clearance) of digoxin, theophylline, cyclosporin, and phenprocoumon via cytochrome P450 and/or P-glycoprotein.34,35 Case series also suggest interactions of St-John's-wort with adrenergic vasopressors, anesthetics, bupropion, cyclosporin, nevirapine, oral contraceptives, paroxetine, phenprocoumon, prednisone, sertraline, tacrolimus, theophylline, warfarin, and so on.31,36,37 Clinical cases indicate interactions of ginkgo (Ginkgo biloba) with antiepileptics, aspirin (acetylsalicylic acid), diuretics, ibuprofen, risperidone, rofecoxib, trazodone, and warfarin.38-40 Moreover, soluble fibers (including guar gum and psyllium) can decrease the absorption of drugs.41 Pharmacokinetic variables can be affected by organ-based changes following irradiation, resulting in change in treatment response or adverse effects.41,42 Blackstock et al noted the tumor retention of 5-FU was prolonged in animals receiving radiation before the drug infusion, and the tumor clearance rate of the 5-FU was a 3-fold reduction in the irradiated tumors.41 Schlemmer et al also noted the 5-FU levels were significantly higher after CCRT when compared with the first chemotherapy delivering.42 A number of animal studies have shown that local irradiation affects the systemic PKs of 5-FU and CDDP regardless of the dose.43-46

Advanced radiotherapy modalities such as 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), helical tomotherapy, and arc radiotherapy allow for the precise delivery of radiation doses to the tumor while sparing critical organs.47-50 Nonetheless, each modality results in a general, low-dose distribution of radiation to the torso.43 Coppes and colleagues found that the out-of-field effects of radiation on vascular damage were very similar to the in-field effects.51 Erpolat et al found that IMRT planning resulted in lower irradiated bone marrow volumes than 3DCRT planning.52

These phenomena imply that irradiation affects the PK of cytotoxic agents and is referred to as the radiotherapy–pharmacokinetic (RT-PK) phenomenon. On the other hand, much less is understood about the biological effects of this phenomenon, especially when advanced, conformal radiation techniques with low-dose distribution are used (Figure 1). In this review, we provide a general overview of the RT-PK phenomenon and discuss the possible mechanisms governing the phenomenon.

Search Methods for Identification of Studies

The medical databases listed below were searched for English publications from their inception to July 2017.
Electronic database searches were performed with MeSH terms and free text terms.

For MeSH terms searching, (1) (“Pharmacokinetics”[Mesh] AND “Radiotherapy”[Mesh]) OR “Cisplatin”[Mesh] OR “Fluorouracil”[Mesh] AND “Rectal Neoplasms”[Mesh]) OR (“Uterine Cervical Neoplasms”[Mesh]) AND “Chemoradiotherapy”[Mesh] AND (“2007/09/06”[PDAT]: “2017/09/02”[PDAT] AND English[lang]) were used, and the numbers of article were 254; (2) (“mitogen-activated protein kinase kinases”[Mesh] OR “Phosphatidylinositol 3-Kinases”[Mesh]) AND “Radiotherapy”[Mesh] were used, and the numbers of article were 56; (3) “Bystander Effect”[Mesh] AND “Radiotherapy”[Mesh] were used, and the numbers of article were 89.

For free text terms searching, we used absorpable effects, bystander effects, irradiation, chemotherapy, concurrent chemoradiation, combined modality, metronomics, PKs, radiotherapy, radio chemotherapy, radiosensitization, rectal neoplasm, and uterine cervical neoplasms. For manual search/abstract search, we searched Cancer, Cancer Letter, Cancer Research, Lancet, Journal of Clinical Oncology, International Journal of Radiation Oncology Biology Physics, Radiotherapy Oncology, New England Journal of Medicine, Nature Review Clinical Oncology. Proceedings were searched from American Society for Radiation Oncology, European Society for Radiotherapy & Oncology, and American Society of Clinical Oncology.

Literature Selection

Unpublished data, case reports, letters, editorials, and comments were excluded from the analysis. Multiple articles published by the same author over a short period were also excluded.

The RT-PK Phenomenon

The RT-PK Phenomenon of 5-FU

In plasma, 5-Fluorouracil increases the radiosensitivity of RT and is metabolized in the liver via a catabolic pathway and an anabolic pathway. The liver catabolizes about 80% of 5-FU via the dihydropyrimidine dehydrogenase (DPD) pathway to generate toxic 5-fluoro-5,6-dihydro-uracil (5-FDH2), and DPD is a rate-limiting step. In the anabolic pathway, 5-FU via orotate phosphoribosyl transferase produces active metabolites including 5-fluourouridine-5'-monophosphate, 5-fluorouridine, and 5-fluoro-2'-deoxyuridine.

Concurrent chemoradiation therapy has been shown to result in better pathological response and local control in rectal cancer than RT alone but that the incidence of grade 3 or 4 toxicity is significantly higher after CCRT (15%-29%) than after RT (0%-6%), no matter of neoadjuvant setting or definitive setting or adjuvant setting. In the meta-analysis of head and neck cancer studies, RT combined with 5-FU or CDDP as a single drug or 5-FU-base chemotherapeutic agents resulted in a large survival advantage. However, CCRT is also associated with high rates of hematologic toxicity and other systemic adverse effects in head and neck cancer treatment.

The PK of 5-FU can be used to predict disease recurrence. Di Paolo and Lencioni found that the area under the curve (AUC) of 5-FU was significantly lower in patients with colorectal cancer with recurrent disease than in patients without disease recurrence. In addition, Milano et al reported that patients with longer 5-FU systemic exposure had longer disease-free survival. In 3 previous studies, we explored the effects of low-dose radiotherapy and practical dose radiotherapy on anticancer drugs in rats. Animals were randomized to receive 0 Gy (control), 0.5 Gy (representing a dose deposited in the off-target area in clinical practice), or 2 Gy and then were administered 5-FU following RT to check the RT-PK phenomena of anticancer drugs.

Intriguingly, whole abdominal irradiation resulted in a 21% reduction in the AUC of 5-FU at 0.5 Gy and a reduction of 32% at 2 Gy. Similarly, pelvic irradiation (excluding the liver and kidneys) resulted in an 18% reduction in the AUC of 5-FU at 0.5 Gy and a 22% reduction at 2 Gy. In bile, there was a 25% increase in the AUC of 5-FU at 0.5 Gy and a 31% increase at 2 Gy. Also, head and neck irradiation significantly reduced the AUC of 5-FU by 17% at 0.5 Gy and by 16% at 2 Gy. In bile, the AUC of 5-FU increased by 12% at 0.5 Gy and by 25% at 2 Gy. Furthermore, the mean residence time of 5-FU following RT decreases in plasma and increases in bile, while the clearance reduces significantly in bile and increases significantly in plasma after RT, but no differences in the volume of distribution at steady state (Vss) between irradiated and control animals.

These findings suggest that local irradiation with or without including the liver and kidneys is able to influence the AUC of 5-FU, no matter by low dose (such as off-target dose in daily practice) or by daily general dose. As mentioned above, the active metabolites of 5-FU are through anabolic pathway. When the AUC of 5-FU is decreased by irradiation, the probability of metabolism of 5-FU through anabolic pathway may be influenced by irradiation. The interaction between irradiation and PKs of 5-FU is discovered and supports the strategy of adjuvant chemotherapy in the clinical practice.
highly absorbable in a gastric emptying-limited manner with first-pass metabolism concerning. In particular, intraluminal injection of 5-FU to submucosa resulted in higher levels of the drug in the colonic wall and abdominal lymph nodes in a dog model. However, to the best of our knowledge, no studies have investigated the dynamic shift of 5-FU from plasma to the lymphatic system after intravenous injection. Furthermore, the biological meaning of drug concentration detected in the gross lymph nodes may differ from that detected in identifiable lymphatic vessels.

Radiation-induced increase in vascular ionizing radiation causes a dose-dependent loss in endothelial cells and hypertrophy of surviving endothelial cells, features associated with enhanced vascular permeability that will be considered as one of the factors responsible for metastatic spread. However, it is dose dependent between 5- and 20-Gy single doses, and the dose that has been shown to cause vascular disease ranges from 25 to 40 Gy. Intriguingly, there were no differences in the AUC of 5-FU in lymphatic fluid between animals that received local pelvic irradiation and those that did not receive irradiation. These findings agreed with the results that single daily RT dose would not change the permeability of vessel or lymphatic system in delivery of 5-FU.

The RT-PK Phenomenon of CDDP

**In plasma.** Meta-analyses have confirmed that both platinum-based and non-platinum-based CCRT result in markedly better treatment outcomes than RT alone in patients with cervical cancer. Nevertheless, a number of studies have found that the rates of hematological toxicities are at 2- to 10-fold greater than those who receive RT alone. The analyses also revealed that the rates of serious GI toxicity were about 2-fold greater in those who have undergone CCRT than in those who have received RT alone.

Recently, whole pelvic irradiation increased the AUC of CDDP (5 mg/kg) by 80% at 0.5 Gy and 87% at 2 Gy, which was noted in the animal study. In the same study, it was found that pelvic irradiation decreased the clearance value of CDDP by 44.9% in the 0.5-Gy group and by 46.6% in the 2-Gy group. Moreover, in bile study, pelvic irradiation decreased the AUC of the CDDP by 13% at both dose levels. Intriguingly, RT also resulted in an 87% increase in AUC of the CDDP in lymphatic system at 2 Gy. Radiotherapy decreased the total plasma clearance (CL) of the CDDP in plasma by 32.0% and in the lymphatic system by 46.8%. The modulating function of pelvic RT in the lymphatic system. Platinum-based regimens administered concurrently with RT have been shown to be associated with a lower risk of locoregional failure and distant metastases than RT alone. It has also been reported that the rate of distant failure was lower in patients who received CDDP than in those who received 5-FU via PVI (29% vs 18%). As mentioned previously, a single daily RT dose does not change the permeability of vessels or the lymphatic system in delivery of 5-FU; however, 2 Gy, a practical daily dose, has been shown in rats to increase the AUC of CDDP in lymphatic fluid by 87% and to decrease the CL of CDDP in the lymphatic system by 46.8%. Additionally, the AUC for CDDP was 3.4-fold greater in the lymphatic system than in plasma from rats that received RT but was 2.8-fold in rats that did not receive RT. These findings indicate that the distribution of CDDP in the lymphatic system could be enhanced by RT.

Modifying chemotherapeutic formulations in a way that increases exposure of the lymphatic system to said drugs might be an effective means of improving drug efficacy. Future studies that provide a better understanding of the relationship between RT and the PK of CDDP in the lymphatic system might shed light on ways to reduce the incidence of regional and distant failure.

**A Possible Mechanism Governing the RT-PK Phenomenon**

Matrix metalloproteinase-8 (MMP-8), a member of the zinc-dependent interstitial collagenase subgroup of the MMP family of neutral proteinases, mediates inflammatory processes. The protein is expressed in response to injury in many cell types, such as neutrophils, macrophages, plasma cells, granulocytes, and epithelial choroid plexus cells. Polymorphonuclear neutrophils (PMNs), the main source of MMP-8 in humans and mice, degrade collagen by releasing members of the MMP family at inflammatory sites.

Several stress response and cell–cell signaling molecules are believed to be involved in bystander signaling or abscopal effects. Molecules that have been proposed as participants in bystander effects include interleukin 6 (IL-6) and IL-8, transforming growth factor-β1, tumor necrosis factor α (TNF-α), reactive oxygen species, and reactive nitrogen species. Molecules that are believed to be involved in producing abscopal effects include TNF-α, IL-4, IL-18, IL-2, and granulocyte–macrophage colony-stimulating factor, cytokines that are known to be released systemically in response to
Although MMP-8 has been demonstrated to play a major role in local RT-induced modulation of systemic 5-FU PK,\textsuperscript{44} it has not been shown to correlate with bystander or abscopal effects.

Neutrophils express a large number of cell surface receptors that stimulate an inflammatory response.\textsuperscript{92} FcγR and CR3 not only act cooperatively to initiate the actin polymerization necessary for neutrophils under stress but also activate nicotinamide adenine dinucleotide phosphate (NADPH) oxidase for O2\textsuperscript{-} production.\textsuperscript{93,94} Polymorphonuclear neutrophils that are exposed to appropriate stimuli activate NADPH oxidase, resulting in the generation of O2\textsuperscript{-}.\textsuperscript{95} Moreover, activation of phosphatidylinositol (PtdIns) 3-kinases (PI3-kinases or PI3 K) leads to the production of PtdIns(3,4,5)P3 (PIP3), and activation of protein kinase B/Akt is reported to occur after PMN stimulation and to be associated with both O2\textsuperscript{-} production and phagocytosis.\textsuperscript{92,96,97}

Stimulation of FcγR and CR3 also activates the p38 mitogen-activated protein kinase (MAPK) in macrophages and PMNs.\textsuperscript{98,99} The 3 main members that integrate the MAPK family in mammalian cells are stress-activated protein kinase c-Jun NH2-terminal kinase, stress-activated protein kinase 2 (p38), and extracellular signal-regulated protein kinases 1 and 2 (p44/p42). The p38 MAPK is involved in the signaling pathway of O2\textsuperscript{-} production.\textsuperscript{100} Inflammatory stimuli also activate p38 MAPK, and a specific inhibitor of p38 MAPK prevents O2\textsuperscript{-} production in PMNs that have been exposed to lipopolysaccharide and N-formyl-methionyl-leucyl-phenylalanine.\textsuperscript{99,101}

Putting these observations together, it is arguable that RT induces inflammatory stress and results in the recruitment of leukocytes to the target area.\textsuperscript{102} Neutrophils degrade collagen by releasing members of the MMP family when they are localized at inflammatory sites.\textsuperscript{92} It promotes the secretion of MMP-8 as well as various other proinflammatory mediators to modulate the PKs of anticancer drugs. Studies have demonstrated that MMP-8 plays an important role in the RT-PK phenomenon.\textsuperscript{44} PI3-K and p38 MAPK participate in signaling pathways governing NADPH oxidase-generated O2\textsuperscript{-} production and phagocytosis. Therefore, it is reasonable to suspect that the MAPK family or the PI3K/Akt signaling pathway contributes to the RT-PK phenomenon. Figure 2 illustrates the possible mechanisms governing the RT-PK phenomenon.

**The RT-PK Phenomena Should Be Considered in the Strategy of the Combination of Radiotherapy With Target or Immunologic Drugs or Metronomic Chemotherapy Schedule**

It is an exciting time for clinical oncologists because we have undergone dramatic changes in routine practice in the last decade. These include the technological advances in radiation modalities,\textsuperscript{47-50} the demonstration of the superiority of chemoradiotherapy over radiotherapy alone,\textsuperscript{19,21-23,27,28,57,58,103} and the integration of novel targeted therapies or immunotherapy within standard combination strategies.\textsuperscript{104,105}

Strategies for improving the efficacy of clinical radiotherapy focus on exploiting actionable tumor-specific molecular targets.\textsuperscript{106} Some case reports also hint the possibility of interaction between RT and target agents.\textsuperscript{107,109} In a phase 2 study about combined sorafenib and radiotherapy in patients with
advanced hepatocellular carcinoma, concurrent group had more grade 3 hand and foot skin reaction and diarrhea than sequential group.\textsuperscript{110} Recently, a poster of animal study accepted by conference of ESTRO 36 confirmed there was RT-PK phenomenon also between sorafenib (target agent for hepatocellular carcinoma) and irradiation.\textsuperscript{111}

A growing body of evidence also shows that the combination of radiotherapy with immunotherapy through abscopal responses can enhance the systemic immune response.\textsuperscript{105,112,113}

Recently, in a preclinical model, combining anti-PD-1 antibody and thoracic irradiation results in T cell infiltration into lung and heart tissue and increases mortality.\textsuperscript{114} This observation mentions the possibility of modulation by irradiation for immunotherapy in the immune system and in the PK.

Metronomic regimens are developed to optimize the antitumor efficacy of agents that target the tumor vasculature instead of tumor cells.\textsuperscript{14,115,116} Unlike dose-dense chemotherapy, deliver anticancer drugs with lower dose and prolonged periods of time to target tumor vasculature.\textsuperscript{11,14} Knowledge of the preclinical PK of metronomic chemotherapies has grown slowly over the past years.\textsuperscript{117} There are several positive results in palliative settings\textsuperscript{118-120} or maintenance treatment.\textsuperscript{121}

Recently, data from the clinical study revealed for the first time a statistically significant relationship between the active drug PK parameters and the clinical response to the metronomic-like chemotherapy regimen.\textsuperscript{122}

Metronomic treatment can be combined with standard chemotherapy,\textsuperscript{123,124} antiangiogenic drugs,\textsuperscript{125,126} antibodies targeting proteins,\textsuperscript{127} or vascular endothelial growth factor receptor -2 and/or vascular endothelial growth factor\textsuperscript{128,129}; anti-HER-2 antibodies\textsuperscript{130}; immunotherapies\textsuperscript{131,132}; or hormonal agents, such as aromatase inhibitors,\textsuperscript{133} among others. In the clinical practice, the regular model of CCRT for RT delivering is continually multiple fractions. As we mention above, RT affects the PKs of 5-FU through MMP-8.\textsuperscript{44} Additionally, irradiation increases the expression of endothelial interacellular adhesion molecules -1 protein\textsuperscript{134} and increases apoptosis in microvascular endothelial cells.\textsuperscript{135} Moreover, the endothelial sheet of vessel could be disrupted by 5-FU.\textsuperscript{136} The data also showed the activity of MMP-8 and MMP-9 was elevated round the damaged aneurysm.\textsuperscript{137} These findings explore the potentially modulated effects of combination of metronomic regimens and RT through RT-PK phenomena. In the future, the knowledge of interaction between the PK characteristics of metronomic regimen and RT may encounter challenges. However, it is worth to investigate the RT-PK phenomena in metronomic regimens to provide a better understanding of the optimal metronomic-dosing regimens concurrent with RT in patients, especially about the onset, intensity, duration, quality of the therapeutic effects, and reduce any harmful effects the drug might have.

Until now, we do not have a good understanding of the relationship between the maximum tolerated dose and the dose/fractionation required to achieve the desired therapeutic effect, especially for targeted agent, immunologic agents, or metronomic regimens combined with mordent radiotherapy modalities. The RT-PK phenomenon suggests that even off-target radiation doses can affect the bioavailability of the radiosensitizing drugs and that the mechanisms of these effects are multifactorial and complex in nature.\textsuperscript{43-46,61} Our current understanding of the systemic effects of localized irradiation governed by the RT-PK phenomenon allow for the establishment of optimal RT parameters that can be incorporated into future treatment strategies.

**The New Era for RT-PK Phenomena—Particle Therapy**

In December 1904, William Henry Bragg and his assistant Richard Kleeman published “On the ionization of curves of radium” in the Philosophical Magazine (London), named the Bragg-peak, that gave measurements of the ionization produced in air by alpha particles and noted a particle is a more efficient ionizer toward the extreme end of its course. In front of the Bragg-peak, the dose level is modest as compared to photon beams; beyond this peak, no further dose deposition occurs.\textsuperscript{138} In the mid-1940s, Robert Wilson hypothesized that highly localized deposition of energy from proton beams could increase the radiation doses to tumors and minimize radiation to adjacent normal tissues. Shortly thereafter, scientists at the Lawrence Berkeley Laboratory initiated the first studies on proton irradiation to confirm this hypothesis.\textsuperscript{139}

Conventional cancer radiation therapy uses several types of ionizing radiation (X-rays, gamma rays, or electron beams) to treat tumors. Ionizing radiation damages the DNA of tumor and healthy cells alike, triggering complex biochemical reactions and eventually resulting in cell death. Charged particles such as protons have little exit dose beyond the target volume, thereby greatly sparing adjacent normal tissues. The dosimetric advantages of protons have been demonstrated in numerous planning studies compared to 3DCRT and IMRT.\textsuperscript{140,141} Additionally, the newly developed intensity-modulated proton therapy has been shown to yield superior dose distributions to photon IMRT, with the added advantage of a significant reduction in the volume of healthy normal tissues exposed to low-to-medium doses.\textsuperscript{142,143} These physical characteristics allows proton beam therapy to improve the therapeutic ratio by limiting toxicities while at the same time delivering higher radiation doses.

The biological effects of proton beams were similar to conventional radiations used in radiotherapy. The relative biological effectiveness of protons suitable for large-field radiotherapy, compared with 60\textsuperscript{Co} gamma rays, is generally in the range 1.0 to 1.25 and remains the same with depth of penetration, except for the descending portion of the depth-dose curve. The oxygen enhancement ratio for high-energy protons is not significantly different from that of X-rays.\textsuperscript{144} The above discussion assumes that the sole difference between photon and proton irradiation is the physical dose distribution and that the biological effect per dose could be equivalent.

As mentioned previously, even off-target radiation doses can modulate the bioavailability of the radiosensitizing
Interestingly, proton beams therapy has Bragg-peak phenomena. Notably, the biological effects of proton beams are similar to the conventional radiotherapy. This characteristic of proton beam makes irradiation doses delivering with restricted off-target doses to the surrounding tissue at the same time. It could be expected the RT-PK phenomenon persists between proton beam therapy and anticancer agents. Additionally, it is also worth to look forward to the possible different expressions of PK between photon and particle therapy.

**Conclusion**

The RT-PK phenomenon provides a clue to understanding the unexplained biological enhancement of antineoplastic agents. Both targeted and off-target RT affect the systemic PK of antineoplastic agents as seen in Figure 3. Further elucidation of the RT-PK phenomenon of antineoplastic agents will give us the opportunity to expand the scope of radiation oncology. It will also allow for the development of new radiation-modulated strategies that do not subject patients to severe toxicity.

**Authors’ Note**

Y. J. Chen and T. H. Tsai contributed to the design and analysis of the work. C. H. Hsieh drafted the manuscript and designed the work. L. Y. Wang gave advice on the work. Y. J. Chen, T. H. Tsai, and L. Y. Wang involved in revising the manuscript. All authors read and approved the final manuscript. Yu-Jen Chen and Tung-Hu Tsai contributed equally to the study.

---

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: This work was supported by the Far Eastern Memorial Hospital (grants FEMH 101-2314-B-418-010-MY3; FEMH 104-2314-B-418-009-MY2) and the Ministry of Science and Technology (grants MOST 101-2314-B-418-010-MY3; MOST 104-2314-B-418-009-MY2).

**References**

1. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. *Int J Radiat Oncol Biol Phys*. 2004;59(4):928-942.
2. Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. *Semin Radiat Oncol*. 2003;13(1):13-21.
3. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. *Cancer Res*. 1988;48(16):4484-4488.
4. Nylen U, Cekan E, Jonasson GB, Lewin F, Skog S. Effects of 5-fluorouracil on cell cycle arrest and toxicity induced by X-irradiation in normal mammalian cells. *Cell Prolif*. 2001;34(2):85-98.
5. Byfield JE. 5-Fluorouracil radiation sensitization–a brief review. *Invest New Drugs*. 1989;7(1):111-116.
6. Bruso CE, Shewach DS, Lawrence TS. Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. *Int J Radiat Oncol Biol Phys*. 1990;19(6):1411-1417.

7. Yoshikawa A, Saura R, Matsubara T, Mizuno K. A mechanism of cisplatin action: antineoplastic effect through inhibition of neovascularization. *Kobe J Med Sci*. 1997;43(3-4):109-120.

8. Britten RA, Evans AJ, Allalunis-Turner MJ, Pearcey RG. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. *Int J Radiat Oncol Biol Phys*. 1996;34(2):367-374.

9. Saxena A, Yashar C, Taylor DD, Gercel-Taylor C. Cellular response to chemotherapy and radiation in cervical cancer. *Am J Obstet Gynecol*. 2005;192(5):1399-1403.

10. Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or fluorouracil and X rays. *Int J Radiat Oncol Biol Phys*. 1982;8(11):1923-1933.

11. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. *Nat Rev Cancer*. 2004;4(6):423-436.

12. Andre N, Carre M, Pasquier E. Metronomics: towards personalized chemotherapy? *Nat Rev Clin Oncol*. 2014;11(7):413-431.

13. Munzone E, Colleoni M. Clinical overview of metronomic chemotherapy in breast cancer. *Nat Rev Clin Oncol*. 2015;12(11):631-644.

14. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. *Cancer Res*. 2000;60(7):1878-1886.

15. Braendengen M, Tveit KM, Berglund A, et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. *J Clin Oncol*. 2008;26(22):3687-3694.

16. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. *J Clin Oncol*. 2006;24(28):4620-4625.

17. Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjunctive Breast and Bowel Project Protocol R-02. *J Natl Cancer Inst*. 2000;92(5):388-396.

18. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. *J Clin Oncol*. 2008;26(35):5802-5812.

19. Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol*. 2009;92(1):4-14.

20. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. *BMC Cancer*. 2006;6:28.

21. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. *J Clin Oncol*. 1999;17(5):1339-1348.

22. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatinum-based radiotherapy and chemotherapy for locally advanced cervical cancer. *N Engl J Med*. 1999;340(15):1144-1153.

23. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N Engl J Med*. 1999;340(15):1154-1161.

24. De Caluwe L, Van Nieuwenhove Y, Ceelen WP. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. *Cochrane Database Syst Rev*. 2013;2:CD006041.

25. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. *N Engl J Med*. 2006;355(11):1114-1123.

26. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. *N Engl J Med*. 1991;324(11):709-715.

27. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. *N Engl J Med*. 1999;340(15):1137-1143.

28. Peters WA III, Liu PY, Barrett RJ, 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *J Clin Oncol*. 2000;18(8):1606-1613.

29. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. *Lancet*. 2001;358(9284):781-786.

30. Jambhekar SS, Breen PJ. *Introduction and Overview*. 1st ed. London, United Kingdom: Pharmaceutical Press; 2009.

31. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. *Drugs*. 2001;61(15):2163-2175.

32. Fugh-Berman A. Herbal medicinals: selected clinical considerations, focusing on known or potential drug-herb interactions. *Arch Intern Med*. 1999;159(16):1957-1958.

33. Fugh-Berman A. Herb-drug interactions. *Lancet*. 2000;355(9198):134-138.

34. Knuppel L, Linde K. Adverse effects of St. John’s Wort: a systematic review. *J Clin Psychiatry*. 2004;65(11):1470-1479.

35. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of *Hypericum perforatum* in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009;33(1):118-127.

36. Izzo AA. Drug interactions with St. John’s Wort (*Hypericum perforatum*): a review of the clinical evidence. *Int J Clin Pharmacol Ther*. 2004;42(3):139-148.
37. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. *Drugs*. 2009; 69(13):1777-1798.
38. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of *Ginkgo biloba* extract. *N Engl J Med*. 1997;336(15):1108.
39. Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with *Ginkgo biloba* and ibuprofen. *Atherosclerosis*. 2003;167(2):367.
40. Matthews MK Jr. Association of *Ginkgo biloba* with intracerebral hemorrhage. *Neurology*. 1998;50(6):1933-1934.
41. Blackstock AW, Kwok L, Branch C, Zeman EM, Tepper JE. Tumor retention of 5-fluorouracil following irradiation observed using 19F nuclear magnetic resonance spectroscopy. *Int J Radiat Oncol Biol Phys*. 1996;36(3):641-648.
42. Schlemmer HP, Becker M, Bachert P, et al. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy. *Cancer Res*. 1999;59(10):2363-2369.
43. Hsieh CH, Hou ML, Liu CY, et al. Abdominal irradiation modulates 5-fluorouracil pharmacokinetics. *J Transl Med*. 2010;8(1):29.
44. Hsieh CH, Liu CY, Hsieh YJ, et al. Matrix metalloproteinase-8 mediates the unfavorable systemic impact of local irradiation on pharmacokinetics of anti-cancer drug 5-fluorouracil. *PLoS One*. 2011;6(6):e21000.
45. Tsai TH, Chen YJ, Hou ML, Tai HC, Hsieh CH. Local pelvic irradiation modulates pharmacokinetics of 5-fluorouracil in the plasma but not in the lymphatic system. *BMC Cancer*. 2015; 15(1):316.
46. Hsieh CH, Hou ML, Wang LY, Tai HC, Tsai TH, Chen YJ. Local pelvic irradiation modulates pharmacokinetics of 5-fluorouracil in the plasma and in the lymphatic system. *Am J Transl Res*. 2015;7(2):375-384.
47. Verhey LJ. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. *Semin Radiat Oncol*. 1999;9(1):78-98.
48. Shueng PW, Lin SC, Chong NS, et al. Total marrow irradiation with helical tomotherapy for bone marrow transplantation of multiple myeloma: first experience in Asia. *Technol Cancer Res Treat*. 2009;8(1):29-38.
49. Tai HC, Hsieh CH, Chao KS, et al. Comparison of radiotherapy strategies for locally advanced hypopharyngeal cancer after resection and ileocolic flap reconstruction. *Acta Otolaryngol*. 2009;129(3):311-317.
50. Infusino E. Clinical utility of RapidArc radiotherapy technology. *Cancer Manag Res*. 2015;7:345-356.
51. Coppes RP, Muijs CT, Faber H, et al. Volume-dependent expression of in-field and out-of-field effects in the proton-irradiated rat lung. *Int J Radiat Oncol Biol Phys*. 2011;81(1):262-269.
52. Erpolat OP, Alco G, Caglar HB, et al. Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: a national multi-center study. *Eur J Gynaecol Oncol*. 2014;35(1):62-66.
53. Bocci G, Danesi R, Di Paolo AD, et al. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. *Clin Cancer Res*. 2000;6(8):3032-3037.
54. Casale F, Canaparo R, Serpe L, et al. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. *Pharmacol Res*. 2004;50(2):173-179.
55. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. *Cancer Res*. 1993;53(22):5433-5438.
56. Regatte S, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. *Cancer Res*. 1987;47(8):2203-2206.
57. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med*. 2004;350(19):1945-1952.
58. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med*. 2004;350(19):1937-1944.
59. Di Paolo A, Lencioni M, Amautari F, et al. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. *Clin Cancer Res*. 2008;14(9):2749-2755.
60. Milano G, Etienne MC, Renee N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. *J Clin Oncol*. 1994;12(6):1291-1295.
61. Hsieh CH, Hou ML, Chiang MH, et al. Head and neck irradiation modulates pharmacokinetics of 5-fluorouracil and cisplatin. *J Transl Med*. 2013;11:231.
62. Clement CC, Rotzschke O, Santambrogio L. The lymph as a pool of self-antigens. *Trends Immunol*. 2011;32(1):6-11.
63. Seto Y, Takenoue T, Nariko H, Kamimishi M. Influence of gastrectomy on the distribution of intravenously administered 5-fluorouracil to regional lymph nodes in an animal model. *Cancer*. 2000;88(11):2443-2446.
64. Lindner P, Heath DD, Shalinsky DR, Howell SB, Naredi P, Hafstrom L. Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide. *Surg Oncol*. 1993;2(2):105-112.
65. Yuasa H, Matsuda K, Gu J, Suzuki E, Yokouchi I, Watanabe J. Dose-dependent gastrointestinal absorption of 5-fluorouracil in rats in vivo. *Biol Pharm Bull*. 1996;19(11):1494-1498.
66. Yuasa H, Gu J, Hayashi Y, Watanabe J. First-pass metabolism of 5-fluorouracil in rats. *J Pharm Pharmacol*. 1998;50(9):1019-1025.
67. Yamada K, Holyoke ED, Douglass HO, Jr. Intraluminal, lymph node, hepatic, and serum levels after intraluminal and intramural injection of 5-fluorouracil in the dog colon. *Am J Surg*. 1976;131(2):253-257.
68. Heisel MA, Laug WE, Stowe SM, Jones PA. Effects of X-irradiation on artificial blood vessel wall degradation by invasive tumor cells. *Cancer Res*. 1984;44(6):2441-2445.
69. Rosen EM, Vinter DW, Goldberg ID. Hypertrophy of cultured bovine aortic endothelium following irradiation. *Radiat Res*. 1989;117(3):395-408.
70. Camplejohn RS, Penhaligon M. The tumour bed effect: a cell kinetic and histological investigation of tumours growing in irradiated mouse skin. *Br J Radiol.* 1985;58(689):443-451.

71. Lindsay S, Kohn HI, Dakin RL, Jew J. Aortic arteriosclerosis in the dog after localized aortic x-irradiation. *Circ Res.* 1962;10:51-60.

72. Lanciano R, Calkins A, Bundy BN, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. *J Clin Oncol.* 2005;23(33):8289-8295.

73. Thomas G, Dembo A, Ackerman I, et al. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. *Gynecol Oncol.* 1998;69(2):137-145.

74. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. *J Clin Oncol.* 2004;22(5):872-880.

75. Ryan GM, Kaminskas LM, Bulitta JB, McIntosh MP, Owen DJ, Porter CJ. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. *J Control Release.* 2013;172(1):128-136.

76. Owen CA, Campbell EJ. The cell biology of leukocyte-mediated proteolysis. *J Leukoc Biol.* 1999;65(2):137-150.

77. Lee EJ, Han JE, Woo MS, et al. Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-alpha activation. *J Immunol.* 2014;193(5):2384-2393.

78. Van Lint P, Libert C. Matrix metalloproteinase-8: cleavage can be decisive. *Cytokine Growth Factor Rev.* 2006;17(4):217-223.

79. VanLambrouck RE, Dejonckheere E, Van Lint P, et al. Matrix metalloproteinase 8-independent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. *J Neurosci.* 2012;32(29):9805-9816.

80. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound metalloproteinase-8: cleavage and solution formulations of doxorubicin. *Cancer Res.* 1999;59(1):54-62.

81. Weiss SJ, Peppin G, Ortiz X, Ragsdale C, Test ST. Oxidative stress signalling: a potential mediator of tumour necrosis factor alpha-induced genomic instability in primary vascular endothelial cells. *Br J Radiol.* 2007;80 Spec No 1:S13-22.

82. Balbin M, Fueyo A, Knauper V, et al. Collagenase 2 (MMP-8) expression in murine tissue-remodeling processes. Analysis of its high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. *J Clin Oncol.* 2005;23(33):8289-8295.

83. Thomas G, Dembo A, Ackerman I, et al. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. *Gynecol Oncol.* 1998;59(1):54-62.

84. Desai S, Kumar A, Laskar S, Pandey BN. Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. *Cytokine.* 2013;61(1):54-62.

85. Iyer R, Lehnert BE, Svensson R. Factors underlying the cell growth-related bystander responses to alpha particles. *Cancer Res.* 2000;60(5):1290-1298.

86. Faccoetti A, Pasi F, Nano R. Some considerations for the study of TGFbeta in medium of irradiated T98G cells: activation, release and consumption. *Anticancer Res.* 2010;30(9):3341-3344.

87. Natarajan M, Gibbons CF, Mohan S, Moore S, Kadhim MA. Oxidative stress signalling: a potential mediator of tumour necrosis factor alpha-induced genomic instability in primary vascular endothelial cells. *Br J Radiol.* 2007;80 Spec No 1:S13-22.

88. Matsumoto H, Tomita M, Otsuka K, Hatashita M, Hamada N. Nitric oxide is a key molecule serving as a bridge between radiation-induced bystander and adaptive responses. *Cancer Chemother Pharmacol.* 2011;4(2):126-134.

89. Tatsumi T, Huang J, Gooding WE, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. *Cancer Res.* 2003;63(19):6378-6386.

90. Hillman GG, Slos P, Wang Y, et al. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. *Cancer Gene Ther.* 2004;11(1):61-72.

91. Nakashima M, Chuma M, Hige S, Asaka M. Abscopal effect on hepatocellular carcinoma. *Am J Gastroenterol.* 2008;103(5):1320-1321.

92. Futosi K, Fodor S, Mocsai A. Reprint of Neutrophil cell surface Fc gamma receptor type 3. *J Immunol.* 2013;172(4):128-136.

93. Krauss JC, Poo H, Xue W, Mayo-Bond L, Todd RF, 3rd, Petty HR. Reconstitution of antibody-dependent phagocytosis in fibroblasts expressing Fc gamma receptor IIIB and the complement receptor type 3. *J Immunol.* 1994;153(4):1769-1777.

94. Heyworth PG, Curnutte JT, Nauseef WM, et al. Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. *J Clin Invest.* 1991;87(1):352-356.

95. Iyer R, Lehnert BE, Svensson R. Factors underlying the cell growth-related bystander responses to alpha particles. *Cancer Res.* 2000;60(5):1290-1298.

96. Faccoetti A, Pasi F, Nano R. Some considerations for the study of TGFbeta in medium of irradiated T98G cells: activation, release and consumption. *Anticancer Res.* 2010;30(9):3341-3344.

97. Natarajan M, Gibbons CF, Mohan S, Moore S, Kadhim MA. Oxidative stress signalling: a potential mediator of tumour necrosis factor alpha-induced genomic instability in primary vascular endothelial cells. *Br J Radiol.* 2007;80 Spec No 1:S13-22.

98. Matsumoto H, Tomita M, Otsuka K, Hatashita M, Hamada N. Nitric oxide is a key molecule serving as a bridge between radiation-induced bystander and adaptive responses. *Cancer Chemother Pharmacol.* 2011;4(2):126-134.

99. Tatsumi T, Huang J, Gooding WE, et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. *Cancer Res.* 2003;63(19):6378-6386.

100. Hillman GG, Slos P, Wang Y, et al. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma. *Cancer Gene Ther.* 2004;11(1):61-72.

101. Nakashima M, Chuma M, Hige S, Asaka M. Abscopal effect on hepatocellular carcinoma. *Am J Gastroenterol.* 2008;103(5):1320-1321.

102. Futosi K, Fodor S, Mocsai A. Reprint of Neutrophil cell surface Fc gamma receptor type 3. *J Immunol.* 2013;172(4):128-136.

103. Krauss JC, Poo H, Xue W, Mayo-Bond L, Todd RF, 3rd, Petty HR. Reconstitution of antibody-dependent phagocytosis in fibroblasts expressing Fc gamma receptor IIIB and the complement receptor type 3. *J Immunol.* 1994;153(4):1769-1777.

104. Heyworth PG, Curnutte JT, Nauseef WM, et al. Neutrophil nicotinamide adenine dinucleotide phosphate oxidase assembly. Translocation of p47-phox and p67-phox requires interaction between p47-phox and cytochrome b558. *J Clin Invest.* 1991;87(1):352-356.

105. Iyer R, Lehnert BE, Svensson R. Factors underlying the cell growth-related bystander responses to alpha particles. *Cancer Res.* 2000;60(5):1290-1298.
p38 mitogen-activated protein kinase cascades in human neutrophils. *J Leukoc Biol.* 1998;64(6):835-844.

100. Yamamori T, Inanami O, Nagahata H, Cui Y, Kuwabara M. Roles of p38 MAPK, PKC and PI3-K in the signaling pathways of NADPH oxidase activation and phagocytosis in bovine polymorphonuclear leukocytes. *FEBS Lett.* 2000;467(2-3):253-258.

101. Nick JA, Avdi NJ, Young SK, et al. Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP. *J Clin Invest.* 1997;99(5):975-986.

102. Garnett CT, Palena C, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. *Lancet Oncol.* 2015;16(7):795-803.

103. Pignon JP, Bourhis J, Domene C, Desguerre L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. *MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet.* 2000;355(9208):949-955.

104. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med.* 2006;354(6):567-578.

105. Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. *Lancet Oncol.* 2015;16(7):795-803.

106. Ree AH, Hollywood D. Design and conduct of early-phase radiotherapy trials with targeted therapeutics: lessons from the PRAVO experience. *Radiother Oncol.* 2013;108(1):3-16.

107. Hsieh CH, Jeng KS, Lin CC, et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. *Clin Drug Investig.* 2009;29(1):65-71.

108. Hsieh CH, Chang HT, Lin SC, et al. Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment—case report. *BMC Cancer.* 2010;10:696.

109. Hsieh CH, Lin SC, Shueng PW, Kuo DY. Recall radiation dermatitis by sorafenib following stereotactic body radiation therapy. *Onco Targets Ther.* 2014;7:1111-1114.

110. Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2014;88(5):1041-1047.

111. Hsieh CH, Wang LY, Tsai TH, Chen YJ. Opposite pharmacokinetics of sorafenib modulates by liver irradiation—concurrent versus sequential Papers presented at: ESTRO 36—The Congress of the European Society for Radiotherapy & Oncology; May 05-09, 2017; Vienna, Austria.

112. Demaria S, Kawashima N, Yang AM, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. *Clin Cancer Res.* 2005;11(2 pt 1):728-734.

113. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. *J Clin Invest.* 2014;124(2):687-695.

114. Myers CJ, Lu B. Decreased survival after combining thoracic irradiation and an anti-PD-1 antibody is correlated with increased T cell infiltration into cardiac and lung tissues. *Int J Radiat Oncol Biol Phys.* 2017(PD-1 thoracic irradiation lung cancer).

115. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. *J Clin Invest.* 2000;105(8):1655-1664.

116. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. *Cancer Res.* 2002;62(23):6938-6943.

117. Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. *Nat Rev Clin Oncol.* 2016;13(11):659-673.

118. Penel N, Clisant S, Dansin E, et al. Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. *Br J Cancer.* 2010;102(8):1207-1212.

119. Patil VM, Noronha V, Joshi A, et al. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. *Oral Oncol.* 2015;51(3):279-286.

120. Chen YM, Fan WC, Tsai CM, et al. A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy. *J Thorac Oncol.* 2011;6(6):1110-1116.

121. Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. *Lancer.* 2015;385(9980):1843-1852.

122. Allegri MG, Di Desidero T, Barletta MT, et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. *Angiogenesis.* 2012;15(2):275-286.

123. Derosa L, Galli L, Orlandi P, et al. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. *Cancer.* 2014;120(24):3923-3931.

124. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. *Cancer Res.* 2005;65(16):7045-7051.

125. Jedeszko C, Paez-Ribes M, Di Desidero T, et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. *Sci Transl Med.* 2015;7(282):282ra250.

126. Cruz-Munoz W, Di Desidero T, Man S, et al. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. *Angiogenesis.* 2014;17(3):661-673.

127. Srivastava K, Hu J, Korn C, et al. Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic...
128. Dellapasqua S, Bagnardi V, Bertolini F, et al. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. *Breast*. 2012;21(3):309-313.

129. Bocci G, Man S, Green SK, et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. *Cancer Res*. 2004;64(18):6616-6625.

130. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. *BMC Cancer*. 2006;6:225.

131. Denies S, Cicchelero L, Van Audenhove I, Sanders NN. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. *J Control Release*. 2014;187:175-182.

132. Weir GM, Hrytsenko O, Stanford MM, et al. Metronomic cyclophosphamide enhances HPV 16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. *Oncoimmunology*. 2014;3(8):e953407.

133. Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. *J Clin Oncol*. 2006;24(22):3623-3628.

134. Cervelli T, Panetta D, Navarra T, et al. Effects of single and fractionated low-dose irradiation on vascular endothelial cells. *Atherosclerosis*. 2014;235(2):510-518.

135. Langley RE, Bump EA, Quartuccio SG, Medeiros D, Braunhut SJ. Radiation-induced apoptosis in microvascular endothelial cells. *Br J Cancer*. 1997;75(5):666-672.

136. Kinhult S, Albertsson M, Eskilsson J, Cwikel M. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. *Scanning*. 2001;23(1):1-8.

137. Wilson WR, Anderton M, Schwalbe EC, et al. Matrix metalloproteinase-8 and -9 are increased at the site of abdominal aortic aneurysm rupture. *Circulation*. 2006;113(3):438-445.

138. Brown A, Suit H. The centenary of the discovery of the Bragg peak. *Radiother Oncol*. 2004;73(3):265-268.

139. Skarsgard LD. Radiobiology with heavy charged particles: a historical review. *Phys Med*. 1998;14 (suppl 1):1-19.

140. Isacsson U, Lennermas B, Grusell E, Jung B, Montelius A, Glimelius B. Comparative treatment planning between proton and x-ray therapy in esophageal cancer. *Int J Radiat Oncol Biol Phys*. 1998;41(2):441-450.

141. Zhang X, Zhao KL, Guerrero TM, et al. Four-dimensional computed tomography-based treatment planning for intensity-modulated radiation therapy and proton therapy for distal esophageal cancer. *Int J Radiat Oncol Biol Phys*. 2008;72(1):278-287.

142. Lomax AJ, Pedroni E, Rutz H, Goitein G. The clinical potential of intensity modulated proton therapy. *Z Med Phys*. 2004;14(3):147-152.

143. Welsh J, Gomez D, Palmer MB, et al. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. *Int J Radiat Oncol Biol Phys*. 2011;81(5):1336-1342.

144. Raju MR. Proton radiobiology, radiosurgery and radiotherapy. *Int J Radiat Biol*. 1995;67(3):237-259.